Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
- PMID: 12579196
- DOI: 10.1038/nm827
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
Abstract
The genetic transfer of antigen receptors provides a means to rapidly generate autologous tumor-reactive T lymphocytes. However, recognition of tumor antigens by cytotoxic T cells is only one step towards effective cancer immunotherapy. Other crucial biological prerequisites must be fulfilled to expand tumor-reactive T cells that retain a functional phenotype, including in vivo cytolytic activity and the ability to travel to tumor sites without prematurely succumbing to apoptosis. We show that these requirements are met by expanding peripheral blood T cells genetically targeted to the CD19 antigen in the presence of CD80 and interleukin-15 (IL-15). T cells expanded in the presence of IL-15 uniquely persist in tumor-bearing severe combined immunodeficiency (SCID)-Beige mice and eradicate disseminated intramedullary tumors. Their anti-tumor activity is further enhanced by in vivo co-stimulation. In addition, transduced T cells from patients with chronic lymphocytic leukemia (CLL) effectively lyse autologous tumor cells. These findings strongly support the clinical feasibility of this therapeutic strategy.
Comment in
-
Cancer T cell therapy expands.Nat Med. 2003 Mar;9(3):257-8. doi: 10.1038/nm0303-257. Nat Med. 2003. PMID: 12612567 No abstract available.
Similar articles
-
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35. doi: 10.1158/1078-0432.CCR-07-0674. Epub 2007 Sep 12. Clin Cancer Res. 2007. PMID: 17855649
-
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.Leukemia. 2015 Feb;29(2):415-22. doi: 10.1038/leu.2014.215. Epub 2014 Jul 9. Leukemia. 2015. PMID: 25005243 Free PMC article.
-
A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.Cancer Res. 2003 Jul 15;63(14):4067-73. Cancer Res. 2003. PMID: 12874008
-
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Int Rev Immunol. 2015. PMID: 25901860 Review.
-
An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells.Cell Immunol. 2021 May;363:104314. doi: 10.1016/j.cellimm.2021.104314. Epub 2021 Feb 23. Cell Immunol. 2021. PMID: 33677140 Review.
Cited by
-
Developing strategies in the immunotherapy of leukemias.Cancer Control. 2013 Jan;20(1):49-59. doi: 10.1177/107327481302000108. Cancer Control. 2013. PMID: 23302907 Free PMC article. Review.
-
Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency.Mol Ther. 2023 Jan 4;31(1):35-47. doi: 10.1016/j.ymthe.2022.08.018. Epub 2022 Aug 31. Mol Ther. 2023. PMID: 36045585 Free PMC article.
-
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system.PLoS One. 2024 Aug 27;19(8):e0309245. doi: 10.1371/journal.pone.0309245. eCollection 2024. PLoS One. 2024. PMID: 39190688 Free PMC article.
-
Adoptive T-cell therapy for Leukemia.Mol Cell Ther. 2014 Aug 12;2:25. doi: 10.1186/2052-8426-2-25. eCollection 2014. Mol Cell Ther. 2014. PMID: 26056592 Free PMC article. Review.
-
How do CARs work?: Early insights from recent clinical studies targeting CD19.Oncoimmunology. 2012 Dec 1;1(9):1577-1583. doi: 10.4161/onci.22524. Oncoimmunology. 2012. PMID: 23264903 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous